| Board of
Directors |
Mr. Mazen Tantash
Chairman &
General Manager |
| Paid
Capital
|
$13,500,000 US
|
| Personnel |
150 employees |
| Company
Classification |
Limited public shareholding
|
|
Markets |
Jordan, Saudi Arabia, Iraq,
Kuwait, Qatar, United Arabs Emirates, Bahrain, Oman, Yemen, Libya, Tunisia,
Algeria, Sudan & other Middle East market. |
| Therapeutic Categories |
Antibiotics: Cephalosporins, Floroqinolones & Doxycyclines
Systemic Antifungals
Antihypertensives: Ca Antagonists, ACEIs, Alpha Blockers
Antiulcerants: PPIs & H2 Antagonists
NSAIDs
Analgesics – Antipyretics
Antidiabetics
Iron & Multivitamin Supplements.
|
| Plants |
Cephalosporin plant : General plant
Certification: cGMP : ISO 9001 & ISO 14001 certification
FDA Approval on design & layout |
| Certification |
Good Manufacturing Practices Certification from the Jordan Ministry of
Health
ISO 9001 and ISO 14001 certification in May 1999 |
| Address |
Mobis- Jerash Highway Street |
| Telephone |
Plant: 962-6-4726723
Marketing office: 962-6-5852470/1/2 |
| Fax |
Plant: ++ 962-6-4725154
Marketing office: ++ 962-6-5852473 |
| E-mail |
Plant:
midpharm@nol.com.jo
Marketing office: midamm@nol.com.jo |
| Web Site |
www.midpharma.com |